LONG-TERM SAFETY AND EFFICACY OF PMPA (TENOFOVIR)

PMPA（替诺福韦）的长期安全性和有效性

• 批准号: 8357237
• 负责人: KOEN K VAN ROMPAY
• 金额: $ 19.14万
• 依托单位: UNIVERSITY OF CALIFORNIA AT DAVIS
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-05-01 至 2012-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8357237
• 关键词: Acquired Immunodeficiency Syndrome; Adenine; Animal Model; Antiviral Agents; California; Funding; Grant; HIV Infections; Human; Macaca; National Center for Research Resources; Newborn Infant; Primates; Principal Investigator; Research; Research Infrastructure; Resources; SIV; Safety; Source; Tenofovir; Therapeutic Effect; Toxic effect; United States National Institutes of Health; Virus Diseases; cost; novel; pinacolyl methylphosphonic acid

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. The objective of this project is to find better and safer antiviral drugs to treat HIV infection. Simian immunodeficiency virus infection of newborn and infant macaques is a useful animal model of human AIDS to evaluate novel antiviral drugs. Previously, we initiated studies to evaluate the long-term therapeutic and toxic effects of tenofovir (9-[2-(phosphonomethoxy)-propyl]adenine; PMPA).

这个子项目是许多利用资源的研究子项目之一 由NIH/NCRR资助的中心拨款提供。子项目的主要支持 而子项目的主要调查员可能是由其他来源提供的， 包括其它NIH来源。 列出的子项目总成本可能 代表子项目使用的中心基础设施的估计数量， 而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。 该项目的目的是寻找更好、更安全的抗病毒药物来治疗HIV感染。猴免疫缺陷病毒感染的新生儿和婴儿猕猴是一个有用的人类艾滋病的动物模型，以评估新的抗病毒药物。以前，我们开始研究，以评估长期的治疗和毒性作用的替诺福韦（9-[2-（膦酰甲氧基）丙基]腺嘌呤; PMPA）。